Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
NCT06085638 · M.D. Anderson Cancer Center · PHASE1/PHASE2 · withdrawn · last registry update 2024-03-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Zero participants accrued” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RARB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-25Results posted on the registry: Hackensack Meridian Health, Daratumumab + Pomalidomide (NCT04700176)
- 2025-02-25Also stopped (terminated): Hackensack Meridian Health, Daratumumab + Pomalidomide (NCT04700176)
- 2025-02-24Results posted on the registry: Syros Pharmaceuticals, Tamibarotene + Venetoclax (NCT04905407)
- 2025-02-24Also stopped (terminated): Syros Pharmaceuticals, Tamibarotene + Venetoclax (NCT04905407)
- 2025-01-28Results posted on the registry: University of Washington, Isotretinoin + dextromethorphan (NCT03076021)
- 2025-01-22Phase 3 first posted: Hasanuddin University, tretinoin 0.025% + Z. officinale patch + tretinoin 0.025% cream (NCT06787222)
- 2025-01-15Phase 3 first posted: Dr.dr.Irma Bernadette, SpKK (K), Cleanser + Combination cream (NCT06775314)
- 2024-12-13Results posted on the registry: Syros Pharmaceuticals, Tamibarotene + Azacitidine (NCT02807558)
- 2024-12-09Also stopped (terminated): Taiho Oncology, Inc., TAS1440 + TAS1440 + ATRA (NCT04282668)
- 2024-11-26Phase 3 first posted: Centre Leon Berard, Vesanoid + Cisplatin (NCT06706401)
- 2024-10-04Results posted on the registry: BeiGene, Dinutuximab Beta + 13-cis-Retinoic Acid (NCT05373901)
- 2024-08-22Results posted on the registry: M.D. Anderson Cancer Center, Vorinostat + Isotretinoin (NCT00555399)
- 2024-08-22Also stopped (terminated): M.D. Anderson Cancer Center, Vorinostat + Isotretinoin (NCT00555399)
- 2024-08-14Results posted on the registry: Children's Oncology Group, Dinutuximab + Irinotecan (NCT04385277)
- 2024-08-07Also stopped (withdrawn): University of Alabama at Birmingham, UAB30 + Placebo (NCT03327064)
- 2024-06-11Phase 3 first posted: Alexandria University, Isotretinoin capsules (NCT06451237)
- 2024-06-07Phase 3 first posted: Centre Hospitalier Universitaire de Nice, ISOtretinoin 5 MG + Topical cream (NCT06447480)
- 2024-05-20Results posted on the registry: Memorial Sloan Kettering Cancer Center, decitabine + tretinoin (NCT00382200)
- 2024-05-17Results posted on the registry: Clementia Pharmaceuticals Inc., Palovarotene dose level 1 + Palovarotene dose level 2 (NCT02279095)
- 2024-05-08Also stopped (terminated): University Hospital Regensburg, low-dose Azacitidine + Pioglitazone (NCT02942758)
- 2024-04-30Results posted on the registry: Icahn School of Medicine at Mount Sinai, 5-Azacitidine + all trans retinoic acid (NCT03572387)
- 2024-04-15Results posted on the registry: Galderma R&D, Adapalene/Benzoyl Peroxide + Adapalene Gel, 0.1% (NCT00422240)
- 2024-03-06Also stopped (withdrawn): University of Oklahoma, Benzoyl peroxide + Adapalene Gel (NCT05536882)
- 2024-03-04Also stopped (terminated): OHSU Knight Cancer Institute, Abemaciclib + Abiraterone (NCT03878524)
- 2024-02-07Also stopped (terminated): Dana-Farber Cancer Institute, Topical Tazarotene (NCT04071756)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision